Skandinaviska Enskilda Banken AB (publ) - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 254 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is 1.26 and the average weighting 0.8%.

Quarter-by-quarter ownership
Skandinaviska Enskilda Banken AB (publ) ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2024$764,687
-18.1%
30,1890.0%0.00%
-20.0%
Q1 2024$933,444
-23.4%
30,1890.0%0.01%
-28.6%
Q4 2023$1,218,730
+153006.8%
30,1890.0%0.01%
+40.0%
Q3 2023$796
-99.9%
30,189
+80.8%
0.01%
+25.0%
Q2 2020$545,00016,7000.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$60,317,00040.05%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$308,746,0006.20%
M28 Capital Management LP 513,300$5,102,0005.33%
GREAT POINT PARTNERS LLC 1,050,000$10,437,0002.51%
Octagon Capital Advisors LP 933,743$9,281,0001.60%
HHLR ADVISORS, LTD. 5,362,014$53,298,0001.40%
VIKING GLOBAL INVESTORS LP 26,620,991$264,613,0001.22%
Cormorant Asset Management, LP 1,469,179$14,604,0001.02%
Fernwood Investment Management, LLC 204,550$2,033,0000.86%
TANG CAPITAL MANAGEMENT LLC 585,424$5,819,0000.71%
View complete list of BRIDGEBIO PHARMA INC shareholders